HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial

BACKGROUND: The phase II multicenter, randomized, open label, therapeutic trial (ISS T-002, Clinicaltrials.gov NCT00751595) was aimed at evaluating the immunogenicity and the safety of the biologically active HIV-1 Tat protein administered at 7.5 or 30 μg, given 3 or 5 times monthly, and at explorin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Retrovirology
Autors principals: Ensoli, Fabrizio, Cafaro, Aurelio, Casabianca, Anna, Tripiciano, Antonella, Bellino, Stefania, Longo, Olimpia, Francavilla, Vittorio, Picconi, Orietta, Sgadari, Cecilia, Moretti, Sonia, Cossut, Maria R Pavone, Arancio, Angela, Orlandi, Chiara, Sernicola, Leonardo, Maggiorella, Maria T, Paniccia, Giovanni, Mussini, Cristina, Lazzarin, Adriano, Sighinolfi, Laura, Palamara, Guido, Gori, Andrea, Angarano, Gioacchino, Di Pietro, Massimo, Galli, Massimo, Mercurio, Vito S, Castelli, Francesco, Di Perri, Giovanni, Monini, Paolo, Magnani, Mauro, Garaci, Enrico, Ensoli, Barbara
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4414440/
https://ncbi.nlm.nih.gov/pubmed/25924841
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12977-015-0151-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars